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Abstract: The lack of an effective anti-viral agent and the emergence of drug-resistant strains dictate a real need for discovery of novel therapies able to amelio-
rate viral infections. In this regards, medicinal plants and natural products offer safe and inexpensive platforms for discovery of efficient and novel anti-viral agents. 
We have investigated the potential anti-viral activities of Veronica persica Poir.  as a medicinal plant against herpes simplex viruses (HSVs). In vitro screening of 
the ethanol plant extract against HSV-1 and HSV-2 infected Vero cells revealed the extract to show a dose-dependent inhibitory activity against both virus strains. 
After fractionation of the extract by a stepwise methanol gradient and evaluation of each fraction, the 80% methanol fraction displayed a pronounced inhibitory 
activity against the herpes viruses. The highest antiviral activity was observed when the Vero cells were treated with the extract both during and after infection by 
viruses. Moreover, the extract showed a prominent synergistic activity in combination with acyclovir anti-HSV therapy. Our findings revealed the potential of V. 
persica extract, especially its 80% methanol fraction, in inhibition of herpes simplex viral infections.
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Introduction
Herpes simplex viruses type 1 (HSV-1) and type 2 
(HSV-2) are responsible for cold sores, encephalitis, 
keratitis and genital herpes. The infections caused by 
these viruses (herpetic infections) are considered very 
common among adults and are dangerous especially 
in immunosuppressed patients (1-3). It is estimated 
that about 65-90% of people all around the world are 
infected by one of the hepes viruses (4). The approved 
drugs for treatment of HSV infections include acyclo-
vir (ACV), penciclovir, valaciclovir, famciclovir, and 
ganciclovir (5). However, the prolonged applications of 
such anti-viral therapies have resulted in the emergence 
of the drug-resistant herpes virus strains (6, 7). There-
fore, because of the appearance of drug-resistant strains 
as well as the absence of an efficient preventive vaccine, 
there exists a real need for the discovery of novel and 
efficient agents for treating these viral infections. 
Medicinal plants with a safe and cost-effective pro-
file, offer a promising option for the treatment of various 
diseases in humans (8-28). So far, many investigations 
have been carried out on screening of medicinal plant 
extracts intended for discovery of new therapeutic 
agents against viral infections (29-38). Such medicinal 
plants can offer alternative treatments with different me-
chanisms of action for managing HSV infections. 
In this context, Veronica species are considered to be 
well-known traditional medicinal plants with a huge the-
rapeutic potential. Until now, the anti-tumor, anti-rheu-
matic and wound healing activity of these species have 
been confirmed by different studies (39-42). Veronica 
persica Poir. or bird's-eye speedwell is a widespread 
Veronica species in eastern Asia and Eurasia (43, 44). 
On account of different medical properties of Veronica 
species, investigation of V. persica extract as a lead for 
the discovery of a novel, natural and effective anti-viral 
agent could be of great interest. In this work, we have 
examined the potential anti-viral activity of V. persica 
extracts on HSV viruses. To our knowledge, this is the 
first report on the antiviral activity of this plant species.
Materials and Methods
Plant material and preparation of extract and frac-
tions
Aerial parts (stems, leaves, and flowers) of Veronica 
persica Poir. were collected during the flowering stage 
in April 2016 from wild plants in the mountains of Mey-
mand, Firuzabad County, Fars Province, Iran. The fresh 
parts of V. persica were used for the preparation of the 
ethanolic extract. The plant material (4000 g) was chop-
ped and triturated with 85% ethanol solution, incuba-
ted at 4oC with shaking for 48 h, and then centrifuged 
at 2000 rpm for 10 min. The supernatant was collec-
ted into a clean flask and the pellet was discarded. The 
solvent was removed from the collected supernatant by 
evaporation. For preparation of a stock solution with a 
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concentration of 10 mg/mL, the extract was dissolved 
in 85% ethanol. The extract was diluted to the appro-
priate concentrations with medium containing 2% fetal 
calf serum. The ethanol extract was fractionated into 
different fractions by reverse phase chromatography 
(RP-C18 Sepack) with a stepwise methanol (MeOH) 
gradient: 0, 20, 40, 60, 80, and 100%. 
Cell culture and herpes simplex virus type 1 and 2 
(HSV-1 and HSV-2)
Vero cell line CCL-81-ATCC (African green monkey 
kidney cells) was grown in monolayer culture in Dul-
becco's Modified Eagle Medium (DMEM) supplement 
with 5% (v/v) fetal calf serum and 100 U/mL penicil-
lin (Gibco), 100 μg/mL streptomycin (Gibco), 2 mM l-
glutamine (Gibco) and 1mM sodium pyruvate (Gibco). 
Then, the cells were incubated at 37o C in humidified air 
containing 5% carbon dioxide (CO2). HSV-1 and HSV-2 
were prepared with cooperation of the Institute Pasteur 
of Iran. Viruses were routinely grown on Vero cell and 
virus stock cultures were prepared from supernatants of 
infected cells and stored at -80 ºC for further tests.
Cytotoxicity assay
The Vero cells were treated with different concen-
trations of the extract and the toxicity of the extract was 
assessed by morphological changes observed by optical 
inverted microscope daily in addition to the MTT assay, 
which was carried out as previously described (45). In 
brief, the cell cultures were incubated with 50 μg/mL 
MTT solution at 37 °C for 5h. MTT is converted by 
mitochondrial succinate dehydrogenase enzyme into in-
soluble formazan. The cultures were washed with saline 
and then sodium dodecyl sulfate solution was added to 
dissolve the formazan. The absorbance was measured 
at 570 nm in a spectrophotometer (Jenway 6405 UV 
models) after 24h incubation at 37 °C, to determine the 
metabolic activity of the cells. The median cytotoxic 
concentrations of the samples (CC50) were determined 
from dose-response curves.
Viral infection assay
The cells were seeded at 2 × 105 cells/well in 96-well 
culture plates, in DMEM with 10% NBCS and antibio-
tics. After 24 h incubation, the medium was removed 
and the cells were infected with 1 PFU (plaque forming 
unit)/cell for 2 hours at 37 °C. The infection develop-
ment was appraised by plaque assay as previously des-
cribed by Huleihel et al. (46). In brief, the unabsorbed 
virus was removed after 2 h infection and cells were 
coated with a layer of 0.6% carboxymethylcellelose 
(CMC). After 48 h post-infection (p.i.), the CMC over-
lay was removed and cell monolayers were mixed with 
10% formalin in saline. The cultures were stained with 
1% crystal violet (Merck, Germany) and plaques were 
counted. The median inhibitory concentrations of test 
samples (IC50) were determined from dose-response 
curves.
Mechanism of antiviral activity
The infected cells were treated with the most active 
MeOH fraction (80%-MeOH) at various times before, 
during or after infection as shown in Table 1.
To examine the direct effect of the tested extract on 
virus particle infectivity, 104 PFU of the suitable virus 
particles were pre-incubated with 10 μg/mL of the 
extract at 25 °C for 35 min. Then these mixtures were 
diluted 104 fold with fresh medium and cell monolayers 
were infected with the diluted mixture. In order to deter-
mine the effect of the extract on intracellular HSV-1 re-
plication, cells were infected for 2 h by HSV-1 without 
extract treatment. Then, the medium was removed and 
replaced with fresh medium with or without the extract 
and the infected cells were removed from the wells by 
treatment with trypsin at 24 h p.i. The obtained cells 
were pelleted by centrifugation at 1500 rpm for 15 min, 
washed 3 times with saline solution. Each pellet was re-
suspended with 100 μL of physiological saline solution 
and the cells were broken by freezing and thawing them. 
The cell debris was removed by centrifugation at 1500 
rpm for 10 min and the mixture containing the endoge-
nous virus was next used for infecting cell monolayers 
(47).
Synergistic effect of plant fraction and acyclovir
The synergistic effect between the most active plant 
MeOH fraction and acyclovir (ACV) against herpes vi-
ruses was evaluated by treating the cells with different 
combinations of the plant fraction and ACV at the time 
and post-infection with the virus (47). Acyclovir (Sig-
ma-Aldrich, St. Louis, MO, USA) was dissolved in dis-
tilled water.
Statistical analysis
The extract was prepared in triplicate for all tests. 
Data were subjected to analysis of variance following a 
completely random design to determine the least signi-
ficant difference (LSD) at P < 0.05 using SPSS v. 11.5 
(IBM SPSS, New York, USA).
Results
After preparation of the V. persica ethanolic extract, 
to check its antiviral activity, HSV-1 and HSV-2-infec-
ted Vero cells were treated by different concentrations 
(0, 5, 10, 15, 30, 60 and 120, µg/mL) of the extract. The 
treatments were at the time and after infection of Vero 
cells by the herpes viruses. After incubation time, there 
• Before infection
• The cell monolayers were incubated with medium containing the 80%-MeOH fraction for 2 
h, afterward the medium was removed and the cells were infected with 1 moi (multiplicity of 
infection) of the virus without additional treatment with the extract fraction
• During infection • The cell culture medium was substituted with medium without the tested extract
• Post infection
• The cells were treated by the extract 2 h after infection with the virus. The treatment was carried 
out without cessation to the end of the test
• During and post infection
• The cells were treated with the extract at the time of infection and the treatment continued to the 
end of the assay
Table1. The infected cells were treated with 80%-MeOH at diffident times of infection.
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showed a significant selectivity and efficacy against 
both viruses (P < 0.05). Moreover, the obtained SI by 
this fraction was 451.6 for HSV-1 and 383.5 for HSV-2. 
The SI values of ACV for HSV-1 and HSV-2 were 340 
and 300, respectively.
To check if there is any correlation between time of 
treatment and the efficacy of the plant extract on viral 
infection, the cells were treated with 80%-MeOH frac-
tion at different time points including before (incubation 
with cells, pre-incubation), during (at infection) and af-
ter cell infection (post infection, p.i.). In addition, the 
cells were treated at two times (at infection and p.i.). 
The optimum results were observed when the treatment 
was performed at two times: during (at infection) and 
post infection (P < 0.05). Sequentially, post infection, at 
infection and pre-incubation treatments were the other 
treatment time points in which the extract showed its 
inhibitory activity against the viruses. Compared to 
was a dose-response effect: increasing concentrations of 
the plant extract, resulted in a decreasing trend in the 
percentage of plaque numbers (PFU) of both viruses. 
At the concentration of 120 µg/mL of the plant ethanol 
extract, the HSV-1 and HSV-2 viruses showed 35% and 
25% significant reduction in PFU %, respectively (P < 
0.05). In all concentrations, the antiviral activity of the 
plant extract was slightly higher for HSV-1 when com-
pared to HSV-2. Such differences were observed espe-
cially at higher concentrations of the plant extract (60 
and 120 µg/mL) (Figure 1).
In a comparative experiment, the selectivity of 
both plant ethanol extract and anti-viral drug acyclovir 
(ACV) against viruses was checked. It was observed 
that the selectivity index (SI, CC50/IC50) values of the 
ethanol extract are significantly lower than the ACV 
ones for both viruses (P < 0.05). In addition, the SI of 
ethanol extract was higher for HSV-1 compared with 
HSV-2 (Figure 2).
After fractionation of the ethanol extract using a 
stepwise methanol (MeOH) gradient, the antiviral acti-
vity of each MeOH fraction was evaluated. CC50, IC50 
and SI for each fraction and ACV as the anti-viral drug 
positive control are summarized in Table 2. Among the 
fractions, 80%-MeOH exhibited the lowest IC50 values 
(0.62 ± 11 for HSV-1 and 0.73 ± 21 for HSV-2), and 
Figure 1. Antiviral activity of V. persica ethanolic extract on 
herpes viruses. Vero cells were infected with 1 moi (multiplicity 
of infection) of different herpes viruses, with or without treat-
ment with various concentrations of plant extract. The cells were 
treated both at the time of infection and again post-infection with 
the extract up to the end of the assay. Plaque numbers (PFU) are 
presented as a percentage of the positive control (infected but 
untreated cell cultures). Values are means ± SD (n=3).
HSV-1 HSV-2
Plant fractions CC50 (µg/mL) IC50 (μg/mL) Selectivity index IC50 (μg/mL) Selectivity index
0%-MeOH 450 ± 66 Inactive - Inactive -
20%-MeOH 360 ± 34 155 ± 75 2.32 220 ± 34 1.63
40%-MeOH 350 ± 45 125 ± 33 2.8 200 ± 29 1.75
60%-MeOH 300 ± 59 85 ± 52 3.52 180 ± 35 1.66
80%-MeOH 280 ± 57 0.62 ± 11 451.6 0.73 ± 21 383.5
100%-MeOH 200 ± 77 60 ± 22 3.33 160 ± 44 1.26 
Acyclovir 150 ± 15 0.44 ± 0.1 340 0.5 ± 0.2 300
Note: Values are mean ± SD (n=3). Vero cell monolayers were treated with different doses of purified fractions of the 
plant extract at the time and after infection.
Table 2. Antiviral activity of V. persica MeOH fractions and acyclovir against herpes viruses.
Figure 2. Selectivity index (SI) of plant ethanol extract and acy-
clovir against HSV-1 and HSV-2. SI was determined as CC50/IC50. 
Values are means ± SD (n=3).
Figure 3. Effect of the treatment time with the plant 80%-MeOH 
fraction on virus infection. Values are mean ± SD (n=3).
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HSV-2, a slightly higher sensitivity of HSV-1 to the 
plant extract was observed at all treatment time points 
(Figure 3).
In further experiments, the synergistic activity of 
both ACV and plant 80%-MeOH fraction on viruses 
was evaluated. After treatment of Vero cells both at 
and after infection time points using a mixture of plant 
fraction and ACV, a synergistic effect was observed (P 
< 0.05): the mixture was able to reduce viral plaques 
of both viruses more than ACV or plant fraction alone 
(Figure 4).
Discussion
Currently, combination therapy is one of the highly 
recommended choices for treatment of viral infections. 
The newly identified genetic diversity among isolated 
human HSV viruses is just one of the reasons that push 
experts toward combination therapies. On the other 
hand, discovery of new therapies is essential not only 
for enhancing the effectiveness of treatment, but also 
for treatment of infections caused by drug-resistant 
HSV strains (48). Currently, one of the main concerns 
about the HSV infections is their progression to a severe 
form and becoming resistant to the common therapies 
such as ACV. In such circumstances, current therapies 
are not able to suppress the viral replication adequately 
and may fail to reduce the cellular viral load patients (6, 
49). Low bioavailability and potency, low efficacy and 
having several side effects by the current HSV infection 
therapies, compel a need for discovery or designing no-
vel treatments without the above-mentioned drawbacks. 
In this context, medicinal plants are one of the safe 
and efficient options in searching for novel antiviral the-
rapies. Screening traditional herbal medicines to obtain 
natural-based antiviral agents with lower side effects, 
higher selectivity and efficacy nowadays is of outmost 
attention. So far, different investigations have been car-
ried out to assess the activity of medicinal plants and 
their products on different viral agents. For instance, in 
one examination, isolated glycosides (saikosaponins A, 
B2, C and D) from traditional medicinal plants showed 
a remarkable antiviral activity upon challenging with 
human coronavirus 22E9 (50). In another experiment, 
the ethanolic and aqueous extracts of Ocimum basilicum 
(sweet basil) were tested on coxsackievirus CVB1. It 
was found that some bioactive compounds derived from 
this plant are able to inhibit the replication of CVB1 
(51). Hydrolysable tannins, isolated from the medicinal 
plant Terminalia chebula, were tested on dengue virus 
in another experiment (52). In this experiment, it was 
observed that punicalagin and chebulagic acid from 
the plant were able to sinactivate the viral particles and 
inhibit their attachments to the host cells. Woodfordia 
fruticosa (53), Bupleurum spp. (54), Silybum maria-
num (55, 56), Corydalis saxicola (57) and Piper longum 
(58) are additional examples of investigated medicinal 
plants that have shown antiviral activities against dif-
ferent viruses such as enterovirus, hepatitis B, hepatitis 
C viruses, etc.
The inhibitory effects of different medicinal plants 
against HSV viruses were also investigated by several 
groups (59-61). In one interesting work, extracted natu-
ral products from the medicinal plant Cassia javanica 
showed potent inhibitory activity of HSV-2 replication 
(61). In another work, hydrolysable tannins extracted 
from some medicinal plants showed a great inhibitory 
action against HSV-1 by targeting the virus glycopro-
teins and finally reducing cellular attachment and host 
cell entrance (62). Melia azedarach (63), Houttuynia 
cordata (64), Rhododendron ferrugineum (65), Myro-
thamnus flabellifolia (66) and Digitalis lanata (67) are 
additional examples of medicinal plants containing va-
rious components with anti-HSV activities. 
In this current work, we have investigated the po-
tential antiviral activity of V. persica extract against the 
HSV viruses. V. persica is one of the famous medicinal 
plants of eastern Asia and Eurasia with a remarkable 
therapeutic potential. So far, the anti-cancer and anti-
rheumatic activities of this plant have been confirmed 
by several researchers (39-42). However, as far as we 
know, there have been no report on evaluation of V. per-
sica extract for any antiviral activities.
After obtaining an ethanol extract of the plant, its 
antiviral activity was checked using both HSV-1 and 
HSV-2 infected Vero cells. Our results revealed an 
antiviral activity of the ethanol extract in a concentra-
tion-dependant manner. However, the selectivity index 
values for the plant ethanol extract were low when com-
pared to ACV as the antiviral medication. Subsequently, 
different MeOH fractions of the extract were obtained 
using reverse phase chromatography, and the antiviral 
activity of each fraction was checked on infected Vero 
cells. According to our results, with the exception of the 
80% MeOH fraction, which showed a remarkable anti-
viral activity with a lower IC50 and higher SI values for 
both HSV-1 and HSV-2, other MeOH fractions showed 
non-significant antiviral activities (P < 0.05). The 80% 
MeOH fraction also exhibited a much higher selectivity 
and efficiency against HSV viruses when compared to 
the antiviral medicine ACV. 
One of the important questions in our experiment 
was the probable effects of pre- and post-infection 
treatments, as well as to examine the effectiveness of 
the plant extract at different infection time points. To 
answer this question, the Vero cells were treated by the 
80% MeOH plant extract fraction before, during and af-
ter infection with HSV viruses. After the experiment, it 
Figure 4. Synergistic effects between plant 80%-MeOH fraction 
and acyclovir. Vero cells were treated independently with 0.1 μg/
mL of plant fraction or 0.01μg/mL acyclovir at and post infection 
with the different viruses, or with a mixture both of those (0.1 μg/
mL of plant fraction and 0.01μg/mL acyclovir). Plaque number 
(PFU) of the treated cultures are presented as a percentage of the 
positive control. Values are mean ± SD (n=3).
15
Antiviral activity of Veronica persica Poir.
Cell Mol Biol (Noisy le Grand) 2018 | Volume 64 | Issue 8 
Javad Sharifi-Rad et al.
was observed that treatment of cells at the time of infec-
tion and again at post infection led to a higher efficacy 
of the extract against viruses. Such findings revealed the 
inhibitory action of the extract on both before and after 
the viral infections and suggest the interfering action of 
the extract on cellular entrance of the viruses. On the 
other hand, the post infection treatment of cells merely 
showed better results in reducing viral plaque forma-
tion when compared to treatment at infection. The 80% 
MeOH fraction also showed a reasonable inhibitory 
effect on endogenous viruses indicating the inhibitory 
activity of the extract on intracellular virus replication. 
Another interesting finding was the higher sensitivi-
ty of HSV-1 to the V. persica extract when compared to 
HSV-2. In almost all anti-viral evaluations using etha-
nol extract and 80% MeOH fraction, HSV-1 showed a 
higher sensitivity to V. persica. This phenomenon also 
was observed in all treatment time points indicating a 
higher effectiveness of the plant extract against HSV-1. 
In order to check the synergistic effects of the extract 
when applied along side the antiviral drug ACV, in a 
separate experiment, specific amounts of 80% MeOH 
fraction of plant extract and ACV were used for treat-
ment at both during and after viral infection of cells. 
The cells which received both ACV and the plant extract 
fraction showed a higher reduction in plaque formation 
by both viruses. Similarly, HSV-1 again showed a higher 
sensitivity especially to the plant extract. Meanwhile, 
the group receiving only the ACV resulted in a similar 
reduction in PFU% of both viruses. These findings exhi-
bited the notable potential of the plant extract in combi-
nation therapies against HSV viruses.
Since most anti-viral therapies still are not ideal to 
completely prevent or inhibit the viral infections, de-
velopment and/or discovering novel and efficient anti-
viral agents is of utmost importance at this time. As 
far as we know, there is no vaccine for prevention of 
HSV infections. On the other hand, researchers still are 
in search for more efficient and safe anti-HSV agents. 
Based on the literature, there are currently no available 
drugs that are able to target the latent HSV-based infec-
tions. In this regard, medicinal plants offer novel poten-
tial and currently are of center of attention as efficient 
sources of anti-microbial and anti-viral agents. Here, we 
have demonstrated the remarkable anti-HSV activity of 
V. persica plant on both HSV-1 and HSV-2 viruses. Our 
results also revealed that the 80% MeOH fraction of the 
V. persica extract is able to significantly reduce the viral 
plaque of both viruses. Considering the importance of 
combination therapy in eradication of viral infections, 
the V. persica extract showed a superior performance 
in inhibition of HSV viruses when applied along with 
ACV. However, more experiments are necessary to 
investigate the applicability and efficiency of combi-
nation therapies using both standard therapeutics and 
natural agents. In conclusion, we introduced V. persica 
as a medicinal plant with anti-HSV activity. However, 
more experiments are recommended to find the specific 
mechanisms of activity of this plant on viruses. We are 
certain that such plants and their products will continue 
to play key roles in drug discovery investigations, espe-
cially for anti-viral drug development.
Acknowledgments 
The authors are grateful to Shahid Beheshti Uni versity 
of Medical Sciences, Tehran, Iran for financial support.
Conflicts of Interest
The authors declare no conflict of interest.
References 
1. Julian K, Lehoang P, Bodaghi B. Herpes Simplex Virus. Intraocu-
lar Inflammation: Springer; 2016: 1165-1179.
2. Diefenbach RJ, Fraefel C. Herpes simplex virus: Springer; 2016.
3. Alyazidi R, Gantt S. Herpes simplex Virus. Congenital and Peri-
natal Infections  2018: 91.
4. Brady RC, Bernstein DI. Treatment of herpes simplex virus infec-
tions. Antiviral Research  2004; 61(2): 73-81.
5. Piret J, Boivin G. Herpesvirus Resistance to Antiviral Drugs. An-
timicrobial Drug Resistance  2017;1185-1211.
6. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleo-
side analogues: mechanisms, prevalence, and management. Antimi-
crobial Agents and Chemotherapy  2011; 55(2): 459-472.
7. Crumpacker CS. Mechanisms of Resistance of Antiviral Drugs 
Active Against the Human Herpes Virus. Antimicrobial Drug Resis-
tance: Springer; 2017: 479-489.
8. Sharifi-Rad M, Varoni EM, Salehi B et al. Plants of the Genus 
Zingiber as a Source of Bioactive Phytochemicals: From Tradition 
to Pharmacy. Molecules  2017; 22(12): 2145.
9. Sharifi-Rad J, Mnayer D, Tabanelli G et al. Plants of the genus 
Allium as antibacterial agents: From tradition to pharmacy. Cellular 
and Molecular Biology (Noisy-le-Grand, France)  2016; 62(9): 57-
68.
10. Sharifi‐Rad J, Salehi B, Varoni EM et al. Plants of the Melaleuca 
genus as antimicrobial agents: From farm to pharmacy. Phytothe-
rapy Research  2017; 31(10): 1475-1494.
11. Sharifi-Rad J, Sureda A, Tenore GC et al. Biological activities of 
essential oils: From plant chemoecology to traditional healing sys-
tems. Molecules  2017; 22(1): 70.
12. Sharifi-Rad J, Salehi B, Stojanović-Radić ZZ et al. Medicinal 
plants used in the treatment of tuberculosis-Ethnobotanical and eth-
nopharmacological approaches. Biotechnology Advances  2017; 
doi: 10.1016/j.biotechadv.2017.07.001.
13. Salehi B, Ayatollahi S, Segura-Carretero A et al. Bioactive che-
mical compounds in Eremurus persicus (Joub. & Spach) Boiss. 
essential oil and their health implications. Cellular and Molecular 
Biology (Noisy-le-Grand, France)  2017; 63(9): 1-7.
14. Sharifi-Rad J, Ayatollahi SA, Varoni EM et al. Chemical compo-
sition and functional properties of essential oils from Nepeta schira-
ziana Boiss. Farmacia  2017; 65(5): 802-812.
15. Sahraie-Rad M, Izadyari A, Rakizadeh S, Sharifi-Rad J. Prepara-
tion of strong antidandruff shampoo using medicinal plant extracts: a 
clinical trial and chronic dandruff treatment. Jundishapur Journal of 
Natural Pharmaceutical Products  2015; 10(4): e21517.
16. Sharifi-Rad M, Tayeboon G, Miri A et al. Mutagenic, antimu-
tagenic, antioxidant, anti-lipoxygenase and antimicrobial activities 
of Scandix pecten-veneris L. Cellular and Molecular Biology (Noi-
sy-le-Grand, France)  2016; 62(6): 8-16.
17. Salehi B, Zucca P, Sharifi‐Rad M et al. Phytotherapeutics in 
cancer invasion and metastasis. Phytotherapy Research  2018; 1-25: 
doi:10.1002/ptr.6087.
18. Bagheri G, Mirzaei M, Mehrabi R, Sharifi-Rad J. Cytotoxic and 
Antioxidant Activities of Alstonia scholaris, Alstonia venenata and 
Moringa oleifera Plants From India. Jundishapur Journal of Natural 
Pharmaceutical Products  2016; 11(3): e31129.
19. Sharifi-Rad J, Fallah F, Setzer W, Entezari RH, Sharifi-Rad M. 
16
Antiviral activity of Veronica persica Poir.
Cell Mol Biol (Noisy le Grand) 2018 | Volume 64 | Issue 8 
Javad Sharifi-Rad et al.
Tordylium persicum Boiss. & Hausskn extract: A possible alternative 
for treatment of pediatric infectious diseases. Cellular and Molecular 
Biology (Noisy-le-Grand, France)  2016; 62(9): 20-26.
20. Sharifi-Rad J, Hoseini-Alfatemi S, Sharifi-Rad M, Miri A. Phy-
tochemical screening and antibacterial activity of different parts of 
the Prosopis farcta extracts against methicillin-resistant Staphylo-
coccus aureus (MRSA). Minerva Biotecnologica  2014; 26(4): 287-
293.
21. Sharifi-Rad J, Mnayer D, Roointan A et al. Antibacterial activi-
ties of essential oils from Iranian medicinal plants on extended-spec-
trum β-lactamase-producing Escherichia coli. Cellular and Molecu-
lar Biology (Noisy-le-Grand, France)  2016; 62(9): 75-82.
22. Sharifi-Rad J, Soufi L, Ayat ollahi S et al. Anti-bacterial effect 
of essential oil from Xanthium strumarium against shiga toxin-pro-
ducing Escherichia coli. Cellular and Molecular Biology (Noisy-le-
Grand, France)  2016; 62(9): 69-74.
23. Sharifi-Rad M, Iriti M, Gibbons S, Sharifi-Rad J. Anti-methicil-
lin-resistant Staphylococcus aureus (MRSA) activity of Rubiaceae, 
Fabaceae and Poaceae plants: A search for new sources of useful 
alternative antibacterials against MRSA infections. Cellular and 
Molecular Biology (Noisy-le-Grand, France)  2016; 62(9): 39-45.
24. Sharifi-Rad M, Tayeboon G, Sharifi-Rad J, Iriti M, Varoni E, 
Razazi S. Inhibitory activity on type 2 diabetes and hypertension 
key-enzymes, and antioxidant capacity of Veronica persica pheno-
lic-rich extracts. Cellular and Molecular Biology (Noisy-le-Grand, 
France)  2016; 62(6): 80-85.
25. Stojanović-Radić Z, Pejčić M, Stojanović N, Sharifi-Rad J, 
Stanković N. Potential of Ocimum basilicum L. and Salvia officina-
lis L. essential oils against biofilms of P. aeruginosa clinical isolates. 
Cellular and Molecular Biology (Noisy-le-Grand, France)  2016; 
62(9): 27-32.
26. Sahraie-Rad M, Izadyari A, Rakizadeh S, Sharifi-Rad J. Prepara-
tion of strong antidandruff shampoo using medicinal plant extracts: a 
clinical trial and chronic dandruff treatment. Jundishapur Journal of 
Natural Pharmaceutical Products  2015; 10(4): e21517.
27. Sharifi-Rad J. Herbal Antibiotics: Moving back into the mains-
tream as an alternative for" Superbugs". Cellular and Molecular Bio-
logy (Noisy-le-Grand, France)  2016; 62(9): 1-2.
28. Sharifi-Rad M, Varoni EM, Iriti M et al. Carvacrol and Human 
Health: A Comprehensive Review. Phytotherapy Research  2018; 
doi: 10.1002/ptr.6103.
29. Salehi B, Kumar NVA, Şener B, Sharifi-Rad M, Kılıç M, Ma-
hady GB, Vlaisavljevic S et al. Medicinal Plants Used in the Treat-
ment of Human Immunodeficiency Virus. International Journal of 
Molecular Sciences 2018; 19(5): 1459.
30. Won J-N, Lee S-Y, Song D-s, Poo H. Antiviral activity of the 
plant extracts from Thuja orientalis, Aster spathulifolius, and Pinus 
thunbergii against influenza virus A/PR/8/34. Journal of Microbio-
logy and Biotechnology  2013; 23(1): 125-130.
31. Akthar MS, Degaga B, Azam T. Antimicrobial activity of es-
sential oils extracted from medicinal plants against the pathogenic 
microorganisms: A review. Issues in Biological Sciences and Phar-
maceutical Research  2014; 2(1): 1-7.
32. Adianti M, Aoki C, Komoto M et al. Anti‐hepatitis C virus com-
pounds obtained from Glycyrrhiza uralensis and other Glycyrrhiza 
species. Microbiology and Immunology  2014; 58(3): 180-187.
33. Huang N-C, Hung W-T, Tsai W-L et al. Ficus septica plant ex-
tracts for treating Dengue virus in vitro. PeerJ  2017; 5: e3448.
34. Gandhi GR, Barreto PG, dos Santos Lima B et al. Medicinal 
plants and natural molecules with in vitro and in vivo activity against 
rotavirus: A systematic review. Phytomedicine  2016; 23(14): 1830-
1842.
35. Park YJ, Moon C, Kang J-H, Choi T-J. Antiviral effects of ex-
tracts from Celosia cristata and Raphanus sativus roots against viral 
hemorrhagic septicemia virus. Archives of Virology  2017; 162(6): 
1711-1716.
36. Sharifi-Rad J, Salehi B, Schnitzler P et al. Susceptibility ofherpes 
simplex virus type 1 to monoterpenes thymol, carvacrol, p-cymene 
and essential oils of Sinapis arvensis L., Lallemantia royleana 
Benth. and Pulicaria vulgaris Gaertn. Cellular and Molecular Bio-
logy (Noisy-le-Grand, France)  2017; 63(8): 42-47.
37. Salehi B, Mishra AP, Shukla I et al. Thymol, thyme and other 
plant sources: health and potential uses. Phytotherapy Research 
2018 ; doi: 10.1002/ptr.6109.
38. Sharifi-Rad M, Mnayer D, Flaviana Bezerra Morais-Braga M et 
al. Echinacea plants as antioxidant and antibacterial agents: From 
traditional medicine to biotechnological applications. Phytotherapy 
Research  2018; doi: 10.1002/ptr.6101.
39. Guerrant RL, Walker DH, Weller PF. Tropical infectious di-
seases: principles, pathogens and practice. Volumes 1 & 2: Churchill 
Livingstone; 1999.
40. Graham J, Quinn M, Fabricant D, Farnsworth N. Plants used 
against cancer–an extension of the work of Jonathan Hartwell. Jour-
nal of Ethnopharmacology  2000; 73(3): 347-377.
41. Küpeli E, Harput US, Varel M, Yesilada E, Saracoglu I. Bioas-
say-guided isolation of iridoid glucosides with antinociceptive and 
anti-inflammatory activities from Veronica anagallis-aquatica L. 
Journal of Ethnopharmacology  2005; 102(2): 170-176.
42. Shahidi Bonjar G, Aghighi S, Karimi Nik A. Antibacterial and 
antifungal survey in plants used in indigenous herbal-medicine of 
south east regions of Iran. Journal of Biological Sciences  2004; 
4(3): 405-412.
43. NRCS U. The PLANTS Database. National Plant Data Center, 
Baton Rouge, LA 70874–4490 USA. 2009.
44. Sharifi-Rad M, Tayeboon G, Sharifi-Rad J, Iriti M, Varoni E, 
Razazi S. Inhibitory activity on type 2 diabetes and hypertension 
key-enzymes, and antioxidant capacity of Veronica persica pheno-
lic-rich extracts. Cellular and Molecular Biology (Noisy-le-Grand, 
France)  2016; 62(6): 80-85.
45. Shi Y, Kornovski BS, Savani R, Turley EA. A rapid, multiwell 
colorimetric assay for chemotaxis. Journal of immunological 
methods  1993; 164(2): 149-154.
46. Huleihel M, Ishanu V, Tal J, Arad SM. Antiviral effect of red 
microalgal polysaccharides on Herpes simplex and Varicella zoster 
viruses. Journal of Applied Phycology  2001; 13(2): 127-134.
47. Abu-Jafar A, Huleihel M. Antiviral activity of Eucalyptus camal-
dulensis leaves ethanolic extract on herpes viruses infection. Inter-
national Journal of Clinical Virology  2017; 1: 001-009.
48. Hodge RV, Field HJ. Antiviral agents for herpes simplex virus. 
Advances in Pharmacology 2013; 67: 1-38.
49. Strasfeld L, Chou S. Antiviral drug resistance: mechanisms and 
clinical implications. Infectious Disease Clinics of North America 
2010; 24(3): 809-833.
50. Cheng PW, Ng LT, Chiang LC, Lin CC. Antiviral effects of sai-
kosaponins on human coronavirus 229E in vitro. Clinical and Expe-
rimental Pharmacology and Physiology  2006; 33(7): 612-616.
51. Chiang LC, Ng LT, Cheng PW, Chiang W, Lin CC. Antiviral 
activities of extracts and selected pure constituents of Ocimum ba-
silicum. Clinical and Experimental Pharmacology and Physiology 
Oct 2005; 32(10): 811-816.
52. Lin LT, Chen TY, Lin SC et al. Broad-spectrum antiviral activity 
of chebulagic acid and punicalagin against viruses that use glycosa-
minoglycans for entry. BMC Microbiology  2013; 13: 187.
53. Choi HJ, Song JH, Park KS, Baek SH. In vitro anti-enterovirus 
71 activity of gallic acid from Woodfordia fruticosa flowers. Letters 
in Applied Microbiology  2010; 50(4): 438-440.
54. Chang JS, Wang KC, Liu HW, Chen MC, Chiang LC, Lin CC. 
Sho-saiko-to (Xiao-Chai-Hu-Tang) and crude saikosaponins inhibit 
17
Antiviral activity of Veronica persica Poir.
Cell Mol Biol (Noisy le Grand) 2018 | Volume 64 | Issue 8 
Javad Sharifi-Rad et al.
hepatitis B virus in a stable HBV-producing cell line. The American 
journal of Chinese Medicine  2007; 35(2): 341-351.
55. Polyak SJ, Morishima C, Lohmann V et al. Identification of 
hepatoprotective flavonolignans from silymarin. Proceedings of 
the National Academy of Sciences of the United States of America 
2010; 107(13): 5995-5999.
56. Polyak SJ, Morishima C, Shuhart MC, Wang CC, Liu Y, Lee DY. 
Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB 
signaling, and HCV infection by standardized Silymarin. Gastroen-
terology  2007; 132(5): 1925-1936.
57. Zeng F-L, Xiang Y-F, Liang Z-R et al. Anti-hepatitis B virus 
effects of dehydrocheilanthifoline from Corydalis saxicola. The 
American Journal of Chinese Medicine  2013; 41(01): 119-130.
58. Jiang Z-Y, Liu W-F, Zhang X-M, Luo J, Ma Y-B, Chen J-J. Anti-
HBV active constituents from Piper longum. Bioorganic and Medi-
cinal Chemistry Letters  2013; 23(7): 2123-2127.
59. Yang CM, Cheng HY, Lin TC, Chiang LC, Lin CC. The in vitro 
activity of geraniin and 1,3,4,6-tetra-O-galloyl-beta-D-glucose iso-
lated from Phyllanthus urinaria against herpes simplex virus type 1 
and type 2 infection. Journal of Ethnopharmacology 4 2007; 110(3): 
555-558.
60. Cheng HY, Yang CM, Lin TC, Lin LT, Chiang LC, Lin CC. 
Excoecarianin, Isolated from Phyllanthus urinaria Linnea, Inhibits 
Herpes Simplex Virus Type 2 Infection through Inactivation of Viral 
Particles. Evidence-based Complementary and Alternative Medicine 
: eCAM  2011; 2011: 259103.
61. Cheng HY, Yang CM, Lin TC, Shieh DE, Lin CC. ent-Epiafze-
lechin-(4alpha-->8)-epiafzelechin extracted from Cassia javanica 
inhibits herpes simplex virus type 2 replication. Journal of Medical 
Microbiology  2006; 55(Pt 2): 201-206.
62. Lin LT, Chen TY, Chung CY et al. Hydrolyzable tannins (chebu-
lagic acid and punicalagin) target viral glycoprotein-glycosamino-
glycan interactions to inhibit herpes simplex virus 1 entry and cell-
to-cell spread. Journal of Virology  2011; 85(9): 4386-4398.
63. Petrera E, Coto CE. Therapeutic effect of meliacine, an antiviral 
derived from Melia azedarach L., in mice genital herpetic infection. 
Phytotherapy Research 2009; 23(12): 1771-1777.
64. Chen SD, Gao H, Zhu QC et al. Houttuynoids A-E, anti-herpes 
simplex virus active flavonoids with novel skeletons from Houttuy-
nia cordata. Organic Letters  2012; 14(7): 1772-1775.
65. Gescher K, Kuhn J, Hafezi W et al. Inhibition of viral adsorption 
and penetration by an aqueous extract from Rhododendron ferrugi-
neum L. as antiviral principle against herpes simplex virus type-1. 
Fitoterapia  2011; 82(3): 408-413.
66. Gescher K, Kuhn J, Lorentzen E et al. Proanthocyanidin-en-
riched extract from Myrothamnus flabellifolia Welw. exerts antiviral 
activity against herpes simplex virus type 1 by inhibition of viral 
adsorption and penetration. Journal of Ethnopharmacology  24 2011; 
134(2): 468-474.
67. Bertol JW, Rigotto C, de Padua RM et al. Antiherpes activity of 
glucoevatromonoside, a cardenolide isolated from a Brazilian culti-
var of Digitalis lanata. Antiviral Research  2011; 92(1): 73-80.
